Skip to main content

Table 4 Analysis of success rate of post-pyloric placement of the nasojejunal tube in prespecified subgroups

From: Metoclopramide or domperidone improves post-pyloric placement of spiral nasojejunal tubes in critically ill patients: a prospective, multicenter, open-label, randomized, controlled clinical trial

Subgroup Metoclopramide group ( n = 100) Domperidone group ( n = 99) Control group ( n = 99) Total ( n = 298) P value
Age      
<60 years 22/38 (57.9)* 19/35 (54.3)* 11/41 (26.8) 52/114 (45.6) 0.0100
≥60 years 33/62 (53.2)* 32/64 (50.0)* 16/58 (27.6) 81/184 (44.0) 0.0090
Sex      
 Male 38/67 (56.7)** 28/58 (48.3)* 17/72 (23.6) 83/197 (42.1) 0.0002
 Female 17/33 (51.5) 23/41 (56.1) 10/27 (37.0) 50/101 (49.5) 0.2944
APACHE II score      
  < 20 31/45 (68.9)** 27/43 (62.8)* 14/43 (32.6) 72/131 (55.0)# 0.0013
  ≥ 20 24/55 (43.6) 24/56 (42.9) 13/56 (23.8) 61/167 (36.5) 0.0398
SOFA score      
  < 12 39/66 (59.1)* 37/68 (54.4) 24/66 (36.4) 100/200 (50.0) 0.0221
  ≥ 12 16/34 (47.1)** 14/31 (45.2)** 3/33 (9.1) 33/98 (33.7) 0.0012
Neurological diseases      
 Yes 27/48 (56.3)** 19/41 (46.3) 9/39 (23.1) 55/128 (43.0) 0.0069
 No 28/52 (53.8)* 32/58 (55.2)* 18/60 (30.0) 78/170 (45.9) 0.0089
Sepsis      
 Yes 9/14 (64.3)* 7/11 (63.6)* 2/13 (15.4) 18/38 (47.4) 0.0173
 No 46/86 (53.5)** 44/88 (50.0)* 25/86 (29.1) 115/260 (44.2) 0.0023
Use of sedatives or analgesics      
 Yes 15/35 (42.9) 16/37 (43.2) 12/38 (31.6) 43/110 (39.1) 0.5023
 No 40/65 (61.5)** 35/62 (56.5)** 15/61 (24.6) 90/188 (47.9) 0.0001
Use of vasopressors      
 Yes 10/24 (41.7) 8/21 (38.1) 4/25 (16.0) 22/70 (31.4) 0.1129
 No 45/76 (59.2)** 43/78 (55.1)** 23/74 (31.1) 111/228 (48.7) 0.0009
Mechanical ventilation      
 Yes 33/72 (45.8) 31/66 (47.0) 19/68 (27.9) 83/206 (40.3) 0.0397
 No 22/28 (78.6)** 20/33 (60.6)* 8/31 (25.8) 50/92 (54.3) 0.0002
  1. Data presented as success/total (%). APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment. *P <0.016, metoclopramide or domperidone group versus controls. **P <0.0033, metoclopramide or domperidone group versus controls. # P = 0.0015, APACHE II score <20 versus ≥20. P = 0.0360, SOFA <12 in the domperidone group versus controls. P = 0.0077, SOFA score <12 versus ≥12. P = 0.0292, neurologic diseases in the domperidone group versus controls. P = 0.0111, use of vasopressors versus without vasopressor. P = 0.0241, mechanical ventilation versus no ventilation.